Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Meningeal Neoplasms × sapanisertib × Thoracic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Lung Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Recurrence 1 Meningeal Neoplasms 1 Brain Neoplasms 1

Interventions

sapanisertib 1 Spinal Puncture 1 Specimen Handling 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04250545 2025-11-25

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡